Best peptides testosterone FAQ

MK-677 is the only growth hormone secretagogue with meaningful oral bioavailability. Peptides like CJC-1295 and ipamorelin are degraded by gastric enzymes before reaching systemic circulation. Research comparing subcutaneous ipamorelin to oral administration found zero detectable GH elevation with oral dosing, even at 10× the subcutaneous dose. For protocols where injections are not feasible, MK-677 at 25mg daily is the mechanistically appropriate alternative, though the continuous GH release pattern differs from the pulsatile secretion produced by injectable peptides.

Discard immediately. Cloudiness indicates either bacterial contamination or protein aggregation, both of which render the peptide inactive and potentially unsafe for research use. Proper reconstitution with bacteriostatic water should produce a clear, colourless solution. Aggregation occurs when peptides are exposed to excessive shaking, temperature fluctuations above 8°C, or low-quality diluent with incorrect pH. The protocol that eliminates this: reconstitute by gently rolling the vial rather than shaking, store at 2–8°C immediately, and use pharmaceutical-grade bacteriostatic water with pH 6.0–7.0.

Verify HPG axis baseline function first. If endogenous LH is already suppressed due to prior exogenous androgen use or hypothalamic hypogonadism, GH secretagogues may amplify pulsatile signalling but cannot overcome primary axis dysfunction. Research published in Andrology found that men with baseline LH below 1.5 IU/L showed minimal testosterone response to ipamorelin after 8 weeks, suggesting that the limiting factor was pituitary LH reserve rather than GH signalling. In these cases, combining a GH secretagogue with hCG (human chorionic gonadotropin). Which directly mimics LH. May restore axis function where GH modulation alone cannot.

Yes, but the mechanism changes. Exogenous testosterone suppresses your natural LH and FSH production, so peptides targeting the HPG axis (like kisspeptin) won't restore endogenous production while you're on TRT. Growth hormone secretagogues like MK 677 and CJC-1295 still work because they act through GH/IGF-1, not the testosterone axis. Men on TRT who add MK 677 report improved body composition, sleep quality, and recovery. Benefits driven by elevated GH rather than further testosterone increases.

Discard it. A peptide left at room temperature (20–25°C) for more than 6–8 hours has undergone partial denaturation. The protein's tertiary structure has been compromised. You can't tell by looking at it, and attempting to use it risks injecting an inactive or partially active compound. The cost of replacing one vial is far lower than the wasted time and effort of continuing a protocol with degraded material.

First, verify your reconstitution and storage methods. Most 'non-responders' had preparation errors. Second, confirm baseline testosterone and IGF-1 levels with bloodwork. If your IGF-1 hasn't increased, the peptide isn't working (whether due to product quality, dosing error, or individual non-response). Third, assess lifestyle factors: inadequate sleep, chronic caloric deficit, or overtraining all suppress the HPG axis and can blunt peptide effects. If all three check out and you're still a non-responder, consider switching peptides or consulting an endocrinologist to rule out primary hypogonadism.

Switch to kisspeptin-10 or verify pulsatile dosing frequency—continuous gonadorelin exposure (daily bolus instead of 90-minute pulses) causes GnRH receptor desensitization within 7–10 days, which suppresses LH secretion rather than stimulating it. The pituitary adapts to sustained GnRH signaling by downregulating receptor density—a protective mechanism against overstimulation. If pulsatile administration is confirmed and LH remains flat, the issue is likely upstream (hypothalamic dysfunction) or downstream (primary hypogonadism where Leydig cells can't respond to LH). Kisspeptin acts earlier in the cascade and may bypass pituitary-level resistance.

Reduce the dose to 12.5 mg daily or switch to hexarelin with twice-weekly dosing instead of daily administration. MK-677 elevates insulin levels by 20–40% in some subjects due to its ghrelin mimetic effects—ghrelin stimulates appetite and insulin secretion simultaneously. The water retention is aldosterone-mediated (GH increases renal sodium retention), and the glucose elevation reflects insulin resistance developing over 8–12 weeks at 25 mg daily. Hexarelin produces similar GH elevation with less chronic ghrelin receptor activation, reducing metabolic side effects while maintaining anabolic outcomes.

Add enclomiphene 12.5 mg every other day to maintain LH signaling during the SARM cycle, or reduce RAD-140 to 5 mg daily and assess whether anabolic effects remain sufficient. Research from 2021 published in Andrology demonstrated that enclomiphene co-administration preserved LH levels at 80% of baseline in subjects using anabolic steroids—the same principle applies to SARMs. The enclomiphene blocks estradiol feedback at the hypothalamus, preventing the suppressive signal that RAD-140's androgenic activity would otherwise trigger. Post-cycle, discontinue the SARM and continue enclomiphene for 4 weeks to accelerate LH recovery.